Advertisement

EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary

Published:January 27, 2009DOI:https://doi.org/10.1016/j.ejca.2008.11.018

      Abstract

      EUROCARE-4 analysed about three million adult cancer cases from 82 cancer registries in 23 European countries, diagnosed in 1995–1999 and followed to December 2003. For each cancer site, the mean European area-weighted observed and relative survival at 1-, 3-, and 5-years by age and sex are presented. Country-specific 1- and 5-year relative survival is also shown, together with 5-year relative survival conditional to surviving 1-year. Within-country variation in survival is analysed for selected cancers.
      Survival for most solid cancers, whose prognosis depends largely on stage at diagnosis (breast, colorectum, stomach, skin melanoma), was highest in Finland, Sweden, Norway and Iceland, lower in the UK and Denmark, and lowest in the Czech Republic, Poland and Slovenia. France, Switzerland and Italy generally had high survival, slightly below that in the northern countries. There were between-region differences in the survival for haematologic malignancies, possibly due to differences in the availability of effective treatments.
      Survival of elderly patients was low probably due to advanced stage at diagnosis, comorbidities, difficult access or lack of availability of appropriate care.
      For all cancers, 5-year survival conditional to surviving 1-year was higher and varied less with region, than the overall relative survival.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Berrino F.
        • Sant M.
        • Verdecchia A.
        • Capocaccia R.
        • Hakulinen T.
        • Estève J.
        Survival of cancer patients in Europe: the EUROCARE Study: IARC Scientific Publications No. 132.
        IARC Press, Lyon1995
        • Berrino F.
        • Capocaccia R.
        • Estève J.
        • et al.
        Survival of cancer patients in Europe: the EUROCARE-2 Study: IARC Scientific Publications No. 151.
        IARC Press, Lyon1999
        • Berrino F.
        • Capocaccia R.
        • Coleman M.P.
        • et al.
        Survival of cancer patients in Europe: the EUROCARE-3 Study.
        Ann Oncol. 2003; 14: 1-155
        • Berrino F.
        • De Angelis R.
        • Sant M.
        • et al.
        EUROCARE Working group. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study.
        Lancet Oncol. 2007; 8: 773-783
        • Verdecchia A.
        • Francisci S.
        • Brenner H.
        • et al.
        Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data.
        Lancet Oncol. 2007; 8: 784-796
        • De Angelis R.
        • Francisci S.
        • Baili P.
        • et al.
        • the EUROCARE Working Group
        The EUROCARE-4 database on cancer survival in Europe: Data standardization, quality control and methods of statistical analysis.
        Eur J Cancer. 2009; 45: 909-930
        • Fritz A.
        • Percy C.
        • Jack A.
        • et al.
        International classification of diseases for oncology.
        third ed. WHO, Geneva1990
        • Hakulinen T.
        Cancer survival corrected for heterogeneity in patient withdrawal.
        Biometrics. 1982; 38: 933-942
        • Corazziari I.
        • Quinn M.
        • Capocaccia R.
        Standard cancer patient population for age standardising survival ratios.
        Eur J Cancer. 2004; 40: 2307-2316
        • Verdecchia A.
        • Guzzinati S.
        • Francisci S.
        • et al.
        • the EUROCARE Working Group
        Survival trends in European cancer patients diagnosed from 1988 to 1999.
        Eur J Cancer. 2009; 45: 1042-1066
        • Patriarca S.
        • Gafà L.
        • Ferretti S.
        • et al.
        Coding criteria of bladder cancer: effects on estimating survival.
        Epidemiol Prev. 2001; 25: 42-47
        • Kvåle R.
        • Auvinen A.
        • Adami H.O.
        • et al.
        Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries.
        J Natl Cancer Inst. 2007; 99: 1881-1887
        • Hankey B.F.
        • Feuer E.J.
        • Clegg L.X.
        • et al.
        Cancer surveillance series: interpreting trends in prostate cancer–part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.
        J Natl Cancer Inst. 1999; 91: 1017-1024
        • Hochhaus A.
        Advances in the treatment of haematological malignancies: optimal sequence of CML treatment.
        Ann Oncol. 2007; 18
        • Shapiro S.
        • Coleman E.A.
        • Broeders M.
        • et al.
        Breast cancer screening programmes in 22 countries: current policies, administration and guidelines. International breast cancer screening network (IBSN) and the European network of pilot projects for breast cancer screening.
        Int J Epidemiol. 1998; 27: 735-742
        • Hewitson P.
        • Glasziou P.
        • Watson E.
        • et al.
        Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update.
        Am J Gastroenterol. 2008;
      1. Tumori. 1997; : 83
        • Paci E.
        • Ponti A.
        • Zappa M.
        • et al.
        Early diagnosis, not differential treatment, explains better survival in service screening.
        Eur J Cancer. 2005; 41: 2728-2734
        • Micheli A.
        • Coebergh J.W.
        • Mugno E.
        • et al.
        European health systems and cancer care.
        Ann Oncol. 2003; 14: v41-v60
        • Oberaigner W.
        • Stühlinger W.
        Record linkage in the cancer registry of Tyrol, Austria.
        Methods Inf Med. 2005; 44: 626-630
        • Vercelli M.
        • Lillini R.
        • Capocaccia R.
        • et al.
        Cancer survival in the elderly: effects of socio-economic factors and health care system features (ELDCARE project).
        Eur J Cancer. 2006; 42: 234-242
        • Quaglia A.
        • Tavilla A.
        • Shack L.
        • et al.
        • the EUROCARE Working Group
        The cancer survival gap between elderly and middle-aged patients in Europe is widening.
        Eur J Cancer. 2009; 45: 1006-1016
        • Micheli A.
        • Mariotto A.
        • Giorgi Rossi A.
        • Gatta G.
        • Muti P.
        The prognostic role of gender in survival of adult cancer patients. EUROCARE Working Group.
        Eur J Cancer. 1998; 34: 2271-2278
        • Micheli A.
        • Ciampichini R.
        • Oberaigner W.
        • et al.
        • the EUROCARE Working Group
        The advantage of women in cancer survival: An analysis of EUROCARE-4 data.
        Eur J Cancer. 2009; 45: 1017-1027
        • Heijnen M.L.
        • Maas H.A.
        • Houterman S.
        • Lemmens V.E.
        • Rutten H.J.
        • Coebergh J.W.
        Comorbidity in older surgical cancer patients: influence on patient care and outcome.
        Eur J Cancer. 2007; 43: 2179-2193
        • Tetsche M.S.
        • Dethlefsen C.
        • Pedersen L.
        • Sorensen H.T.
        • Norgaard M.
        The impact of comorbidity and stage on ovarian cancer mortality: a nationwide Danish cohort study.
        BMC Cancer. 2008; 8: 31
      2. The Globocan 2002 database. http://www-dep.iarc.fr/globocan/database.htm (accessed 05.05.07).

        • Verdecchia A.
        • Corazziari I.
        • Gatta G.
        • Lisi D.
        • Faivre J.
        • Forman D.
        EUROCARE Working Group. Explaining gastric cancer survival differences among European countries.
        Int J Cancer. 2004; 109: 737-741
        • Capocaccia R.
        • Sant M.
        • Berrino F.
        • Simonetti A.
        • Santi V.
        • Trevisani F.
        EUROCARE Working Group. Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century.
        Am J Gastroenterol. 2007; 102: 1661-1670
        • Trevisani F.
        • Cantarini M.C.
        • Labate A.M.
        • et al.
        Italian liver cancer (ITALICA) group. Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival.
        Am J Gastroenterol. 2004; 99: 1470-1476
        • Bach P.B.
        • Jett J.R.
        • Pastorino U.
        • Tockman M.S.
        • Swensen S.J.
        • Begg C.B.
        Computed tomography screening and lung cancer outcomes.
        JAMA. 2007; 297: 953-961
        • Veronesi G.
        • Bellomi M.
        • Mulshine J.L.
        • et al.
        Lung cancer screening with low-dose computed tomography: A non-invasive diagnostic protocol for baseline lung nodules.
        Lung Cancer. 2008; ([Epub ahead of print])
        • Pacifico M.D.
        • Pearl R.A.
        • Grover R.
        The UK Government two-week rule and its impact on melanoma prognosis: an evidence-based study.
        Ann R Coll Surg Engl. 2007; 89: 609-615
        • Owen T.
        • Fitzpatrick D.
        • Dolon O.
        • Gavin A.
        Knowledge, attitudes and behaviour in the sun: the barriers to behavioural changes in Northern Ireland.
        Ulster Med J. 2004; 73: 96-104
      3. Quinn M, Babb P, Brock A, Kirby L, Jones J. Cancer trends in England and Wales 1950–1999. National Statistics 2001.

        • Sant M.
        • Francisci S.
        • Capocaccia R.
        • Verdecchia A.
        • Allemani C.
        • Berrino F.
        Time trends of breast cancer survival in Europe in relation to incidence and mortality.
        Int J Cancer. 2006; 119: 2417-2422
        • Sant M.
        • Allemani C.
        • Capocaccia R.
        • et al.
        Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe.
        Int J Cancer. 2003; 106: 416-422
        • Gentil-Brevet J.
        • Colonna M.
        • Danzon A.
        • et al.
        The influence of socio-economic and surveillance characteristics on breast cancer survival: a French population-based study.
        Brit J Cancer. 2008; 98: 217-224
        • Badgwell D.
        • Bast Jr., R.C.
        Early detection of ovarian cancer.
        Dis Markers. 2007; 23: 397-410
        • Vernooij F.
        • Heintz A.P.
        • Witteveen P.O.
        • van der Heiden-van der Loo M.
        • Coebergh J.W.
        • van der Graaf Y.
        Specialized care and survival of ovarian cancer patients in The Netherlands: nationwide cohort study.
        J Natl Cancer Inst. 2008; 100: 399-406
        • Potosky A.L.
        • Miller B.A.
        • Albertsen P.C.
        • Kramer B.S.
        The role of increasing detection in the rising incidence of prostate cancer.
        JAMA. 1995; 273: 548-552
        • Brenner H.
        • Arndt V.
        Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis.
        J Clin Oncol. 2005; 23: 441-447
        • Etzioni R.
        • Penson D.F.
        • Legler J.M.
        • et al.
        Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends.
        J Natl Cancer Inst. 2002; 94: 981-990
        • Merrill R.M.
        • Wiggins C.L.
        Incidental detection of population-based prostate cancer incidence rates through transurethral resection of the prostate.
        Urol Oncol. 2002; 7: 213-219
        • Baade P.D.
        • Coory M.D.
        • Aitken J.F.
        International trends in prostate-cancer mortality: the decrease is continuing and spreading.
        Cancer Causes Control. 2004; 15: 237-241
        • Collin S.M.
        • Martin R.M.
        • Metcalfe C.
        • et al.
        Prostate-cancer mortality in the USA and UK in 1975–2004: an ecological study.
        Lancet Oncol. 2008; 9 (Epub 2008 April 16): 445-452
        • Levi J.A.
        • Thomson D.
        • Harvey V.
        • et al.
        Effective salvage chemotherapy with etoposide, dactinomycin, and methotrexate in refractory germ cell cancer. Australasian germ cell trial group.
        J Clin Oncol. 1990; 8: 27-32
        • Collette L.
        • Sylvester R.J.
        • Stenning S.P.
        • Fossa S.D.
        • Mead G.M.
        • de Wit R.
        • et al.
        Impact of the treating institution on survival of patients with ‘poor-prognosis’ metastatic nonseminoma.
        J Natl Cancer Inst. 1999; 91: 816-818
        • Sant M.
        • Aareleid T.
        • Artioli M.E.
        • et al.
        Ten-year survival and risk of relapse for testicular cancer: a EUROCARE high resolution study.
        Eur J Cancer. 2007; 43: 585-592
        • Lamm D.
        Bladder cancer: improving care with better classification and risk stratification.
        J Urol. 2007; 178: 1146-1147
        • Holmäng S.
        • Amsler-Nordin S.
        • Carlson K.
        • Holmberg E.
        • Johansson S.L.
        Completeness and correctness of registration of renal pelvic and ureteral cancer in the Swedish Cancer Registry Scand.
        J Urol Nephrol. 2008; 42: 12-17
        • Capocaccia R.
        • Gatta G.
        • Roazzi P.
        • et al.
        The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysis.
        Ann Oncol. 2003; 14: v14-v27
        • Mungan N.A.
        • Aben K.K.
        • Schoenberg M.P.
        • et al.
        Gender differences in stage-adjusted bladder cancer survival.
        Urology. 2000; 55: 876-880
        • Lee C.T.
        • Katz J.
        • Fearn P.A.
        • Russo P.
        Mode of presentation of renal cell carcinoma provides prognostic information.
        Urol Oncol. 2002; 7: 135-140
        • Hardarson S.
        • Magnusson J.
        • Einarsson G.V.
        Effect of incidental detection for survival of patients with renal cell carcinoma: results of population-based study of 701 patients.
        Urology. 2005; 66: 1186-1191
        • De Vita V.T.
        • Serpick A.
        • Carbone P.P.
        Combination chemotherapy in the treatment of Hodgkin’s disease.
        Ann Int Med. 1970; 73: 881-895
        • O’Connor O.A.
        Developing new drugs for the treatment of lymphoma.
        Eur J Haematol Suppl. 2005; : 150-158
        • Mitsiades C.S.
        • Hayden P.J.
        • Anderson K.C.
        • Richardson P.G.
        From the bench to the bedside: emerging new treatments in multiple myeloma.
        Best Pract Res Clin Haematol. 2007; 20: 797-816